Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Standard of Care Treatment · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| KYV-101 CAR-T cells with lymphodepletion conditioning | EXPERIMENTAL | Phase 2: Dosing with KYV-101 CAR-T cells |
| KYV-101 Treatment | EXPERIMENTAL | Phase 3 |
| Standard of Care | ACTIVE_COMPARATOR | Phase 3 Optional crossover to receive KYV-101 Treatment after 24 weeks |
| Name | Type | Description |
|---|---|---|
| Standard of Care Treatment | DRUG | Standard of Care Medications Optional Crossover to receive KYV-101 treatment |
| Standard lymphodepletion regimen | DRUG | Standard lymphodepletion regimen |
| KYV-101 | BIOLOGICAL | Anti-CD19 CAR-T cell therapy |
Key Inclusion Criteria 1. Presence of autoantibodies to AChR or MuSK 2. Myasthenia Gravis Foundation of America (MGFA) Class II-IV 3. MG-Activities of Daily Living (MG-ADL) total score of ≥6 at screening and confirmed at baseline visit 4. QMG total score of ≥11 at screening an confirmed at baseline...
Standard of Care Treatment is being studied for use in Myasthenia Gravis, specifically generalized myasthenia gravis. It is an investigational therapy currently in Phase 2 clinical development. The treatment is being evaluated in a clinical trial enrolling patients with this condition.
Standard of Care Treatment is being developed by Kyverna Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol KYTX. The company is conducting clinical research on this therapy for the treatment of myasthenia gravis.
Standard of Care Treatment is currently in Phase 2 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants to evaluate the treatment for generalized myasthenia gravis.
Standard of Care Treatment is being studied in a Phase 2 clinical trial with the identifier NCT06193889. This trial, titled KYSA-6, is recruiting patients with generalized myasthenia gravis. The study is active and enrolling participants in multiple countries including the United States, Australia, Brazil, Germany, Saudi Arabia, and the United Kingdom.
Standard of Care Treatment is not the same as KYSA-6. KYSA-6 is the name of the clinical trial, not the drug itself. The trial, identified as NCT06193889, is evaluating Standard of Care Treatment in patients with generalized myasthenia gravis. The drug is being developed by Kyverna Therapeutics.